Icometrix NV
icometrix is dedicated to transforming neurology care through brain imaging AI solutions. Their mission is to improve the lives of patients with neurological disorders by providing clinicians with clear, actionable insights from complex scans. They develop validated, FDA-cleared AI tools that support diagnosis, monitoring, and treatment evaluation for conditions like multiple sclerosis, dementia, stroke, traumatic brain injury, epilepsy, Parkinson’s disease, and brain tumors. With a focus on precision and personalized medicine, icometrix aims to enable data-driven clinical decisions and improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Icometrix NV
Kolonel Begaultlaan 1b/12, 3012 Leuven, Belgium
Patents
Products
Cloud-enabled brain MRI analysis platform
A cloud-enabled analytics platform that ingests MRI DICOM data, runs validated AI models to produce segmentations, volumetrics, lesion quantification and structured clinical reports, with outputs delivered back to hospital systems.
Cloud-enabled brain MRI analysis platform
A cloud-enabled analytics platform that ingests MRI DICOM data, runs validated AI models to produce segmentations, volumetrics, lesion quantification and structured clinical reports, with outputs delivered back to hospital systems.
Services
Installation and configuration of local DICOM routing components, integration with PACS/RIS/EMR, and set up of automated data flows and reporting templates.
Support for clinical studies, multi-center validation, publication collaborations and health-economic analyses to validate diagnostic performance and clinical impact.
Provision of regulatory certificates, security questionnaires, data processing agreement templates and documentation required for procurement and medical device deployment.
Advisory support and documentation related to existing reimbursement codes and payer coverage to facilitate billing and adoption.
Installation and configuration of local DICOM routing components, integration with PACS/RIS/EMR, and set up of automated data flows and reporting templates.
Support for clinical studies, multi-center validation, publication collaborations and health-economic analyses to validate diagnostic performance and clinical impact.
Provision of regulatory certificates, security questionnaires, data processing agreement templates and documentation required for procurement and medical device deployment.
Advisory support and documentation related to existing reimbursement codes and payer coverage to facilitate billing and adoption.
Expertise Areas
- Quantitative brain MRI analysis
- Longitudinal neuroimaging monitoring
- Neuroradiology-focused AI/ML
- Clinical validation and multicenter evidence generation
Key Technologies
- Deep learning-based image segmentation
- Volumetric MRI analysis
- Longitudinal image comparison and change detection
- Susceptibility-weighted imaging analysis
News & Updates
Presentation at RSNA 2023 showcasing AI-driven neuroimaging solutions.
icometrix announces the market approval of icobrain aria, the first market-approved solution for monitoring amyloid-related abnormalities.
Validation of icobrain aria as a breakthrough in Alzheimer’s disease management.
FDA and CE-marked solutions
icometrix has FDA and CE-marked solutions, including validated AI tools for multiple sclerosis and icobrain aria.
Market approval for icobrain aria
First AI solution for monitoring amyloid-related abnormalities approved for market.
Research grant awarded to develop biomarkers for Parkinson’s disease.
Presentation at RSNA 2023 showcasing AI-driven neuroimaging solutions.
icometrix announces the market approval of icobrain aria, the first market-approved solution for monitoring amyloid-related abnormalities.
Validation of icobrain aria as a breakthrough in Alzheimer’s disease management.
FDA and CE-marked solutions
icometrix has FDA and CE-marked solutions, including validated AI tools for multiple sclerosis and icobrain aria.
Market approval for icobrain aria
First AI solution for monitoring amyloid-related abnormalities approved for market.
Research grant awarded to develop biomarkers for Parkinson’s disease.